Activating the Immune System to Fight COVID-19

CPI-006 is an immunomodulatory antibody that binds to immune cells, leading to activation of B cells and antibody production that we believe will destroy the SARS-CoV-2 virus.

Our Phase 1 study of CPI-006 demonstrated that it is safe and was associated with meaningful clinical benefits for mild or moderately ill COVID-19 patients. This includes no patients progressing to mechanical ventilation and a median time to discharge from hospital of 3.5 days1. The Company is now enrolling a ~1,000 patient randomized, placebo-controlled Phase 3 study, in COVID-19 patients who are hospitalized with mild to moderate symptoms.

Based on pre-clinical and clinical data, we believe CPI-006 will be a safe and effective therapy that provides several unique advantages in the treatment of COVID-19:

  • Single Low Dose – delivered via a convenient IV infusion over 10 minutes with the potential for subcutaneous administration in the future.
  • Polyclonal – generates antibodies that bind to various subdomains, which is expected to make it more effective than passive monoclonal antibody therapy, and reduce the chance of immune evasion.
  • Durable Immunity – sustains high titer antibody responses and increases memory B cells that are responsible for long-term immunity. 
  • Reduced Immune Evasion – polyclonal antibody response to multiple viral proteins, and to variants, should reduce immune evasion.

This approach has the potential to be a foundational therapy for SARS-CoV-2, SARS-CoV-2 mutant variants, other coronaviruses or future pandemics.

1 January 27, 2021

 

COVID-19 Publications and Presentations

Presentations


Immunotherapy with B cell activating antibody CPI-006 in patients with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells, and memory T effector cells

Gerard Criner, M.D., Chair & Professor, Thoracic Medicine & Surgery, Lewis Katz School of Medicine at Temple University

Oral presentation at the 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting


Immunotherapy with B cell activating antibody CPI-006 in patients with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells, and memory T effector cells

Criner G1, Mobasher M2, Hill C2, Hu S2, Mahabhashyam S2, Brody J3, Marron T3, Willingham S2, Miller R2 

1Temple University Hospital, Philadelphia, PA, USA; 2Corvus Pharmaceuticals Inc, Burlingame, CA, USA; 3Icahn School of Medicine at Mount Sinai, New York, NY, USA 

Poster presentation at the 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

Publications


The following contains links to certain websites owned and operated by third parties. If you use these links you leave our website. These links are provided for your information and convenience only and are not an endorsement by Corvus Pharmaceuticals, Inc. of the content of such linked websites. Corvus has no control of the content of any linked website and is not responsible for these websites or their content or availability. Corvus therefore makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by or the information contained on them.


Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

Stephen B. Willingham, Gerard Criner, Craig Hill, Shenshen Hu, Jenny A. Rudnick, Barbara Daine-Matsuoka, Jessica Hsieh, Haider Mashhedi, Andrew N. Hotson, Joshua Brody, Thomas Marron, Emily Piccione, Joseph J. Buggy, Suresh Mahabhashyam, William B. Jones, Mehrdad Mobasher, and Richard A. Miller

medRxiv doi: 10.1101/2020.09.10.20191486

Our Science

We are developing  immunology focused medicines that target the most critical cellular elements of the immune system

Join Our Team

Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer, immune disorders and infectious diseases